Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 1713 | 18.67 |
09:34 ET | 100 | 18.73 |
09:36 ET | 100 | 18.685 |
09:38 ET | 600 | 18.78 |
09:39 ET | 1592 | 18.86 |
09:41 ET | 746 | 18.8 |
09:45 ET | 636 | 18.75 |
09:48 ET | 100 | 18.72 |
09:52 ET | 200 | 18.71 |
09:56 ET | 200 | 18.725 |
09:57 ET | 100 | 18.725 |
09:59 ET | 600 | 18.7 |
10:01 ET | 400 | 18.71 |
10:03 ET | 354 | 18.73 |
10:10 ET | 200 | 18.69 |
10:12 ET | 400 | 18.71 |
10:14 ET | 100 | 18.7 |
10:15 ET | 2747 | 18.69 |
10:17 ET | 100 | 18.69 |
10:26 ET | 400 | 18.69 |
10:28 ET | 100 | 18.7 |
10:32 ET | 100 | 18.685 |
10:33 ET | 625 | 18.66 |
10:35 ET | 613 | 18.64 |
10:37 ET | 100 | 18.65 |
10:39 ET | 800 | 18.67 |
10:42 ET | 156 | 18.68 |
10:44 ET | 100 | 18.66 |
10:46 ET | 328 | 18.67 |
10:50 ET | 200 | 18.7 |
10:51 ET | 500 | 18.69 |
10:53 ET | 200 | 18.66 |
11:04 ET | 200 | 18.67 |
11:08 ET | 200 | 18.65 |
11:09 ET | 100 | 18.665 |
11:11 ET | 400 | 18.65 |
11:13 ET | 438 | 18.62 |
11:15 ET | 100 | 18.63 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 218.7x | --- |
Dynavax Technologies Corp | 1.4B | 225.3x | --- |
Zai Lab Ltd | 1.7B | -5.0x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.7x | --- |
Maravai LifeSciences Holdings Inc | 1.7B | -7.3x | --- |
MannKind Corp | 1.4B | 222.4x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 218.7x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 121.0x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.